<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>WHO issues alert against substandard oral cough syrups in India</title>
    <link>https://www.taxtmi.com/news?id=58715</link>
    <description>The WHO warns that specific batches of Coldrif, Respifresh TR and ReLife are substandard due to Diethylene Glycol contamination; implicated sites have had production halted, product authorisations suspended and recalls initiated. National regulatory authorities and law enforcement are urged to notify WHO immediately if detections occur, conduct targeted market surveillance-especially of informal supply chains-and assess risks for other oral liquids from the same manufacturing sites. Healthcare professionals must report detections and adverse events to national regulators or pharmacovigilance centres, and contaminated products should be removed from circulation.</description>
    <language>en-us</language>
    <pubDate>Tue, 14 Oct 2025 11:16:03 +0530</pubDate>
    <lastBuildDate>Tue, 14 Oct 2025 11:16:03 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=858306" rel="self" type="application/rss+xml"/>
    <item>
      <title>WHO issues alert against substandard oral cough syrups in India</title>
      <link>https://www.taxtmi.com/news?id=58715</link>
      <description>The WHO warns that specific batches of Coldrif, Respifresh TR and ReLife are substandard due to Diethylene Glycol contamination; implicated sites have had production halted, product authorisations suspended and recalls initiated. National regulatory authorities and law enforcement are urged to notify WHO immediately if detections occur, conduct targeted market surveillance-especially of informal supply chains-and assess risks for other oral liquids from the same manufacturing sites. Healthcare professionals must report detections and adverse events to national regulators or pharmacovigilance centres, and contaminated products should be removed from circulation.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Tue, 14 Oct 2025 11:16:03 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=58715</guid>
    </item>
  </channel>
</rss>